Cargando...
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
In the phase 3 ENDEAVOR study, carfilzomib-dexamethasone (Kd) improved survival over bortezomib-dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM), regardless of baseline renal function. This real-world study compared renal response in patients with RRMM (1-3 prior li...
Guardado en:
| Publicado en: | Blood Adv |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7839365/ https://ncbi.nlm.nih.gov/pubmed/33496733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001059 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|